---
schema_version: "secwatch.filing_event.v1"
accession: "0001411690-24-000046"
form_type: "8-K"
ticker: "BNGO"
cik: "0001411690"
company_name: "Bionano Genomics, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:41:02.249243+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Bionano Q2 revenue $7.8M (-10% YoY); FY2024 guidance $36-40M; retires $15.3M notes

## Summary
- Q2 2024 revenue $7.8M, down 10% YoY; GAAP gross margin 33% vs 27% in Q2 2023.
- GAAP operating expense $19.6M, down 53% YoY; non-GAAP $18.8M, down 46%.
- Cash and securities $30.3M as of June 30, with $11.4M restricted; $20M in debentures outstanding.
- Retired $15.3M convertible notes for $17.6M redemption plus $2.2M fee, funded by $18M private placement of senior secured convertible debentures.
- Guides full year 2024 revenue $36-40M; Q3 2024 revenue expected $7.9-8.9M.

## SEC filing metadata
- accession: 0001411690-24-000046
- form_type: 8-K
- ticker: BNGO
- cik: 0001411690
- company_name: Bionano Genomics, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411690/000141169024000046/0001411690-24-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411690/000141169024000046/bngo-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411690-24-000046
- JSON: https://secwatch.observer/filing/0001411690-24-000046.json
- Plain text: https://secwatch.observer/filing/0001411690-24-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.